AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Spironolactone in 2024: Rationale for Use, Mechanism of Action, and Patient Selection

Description

The presentation discusses the use of spironolactone in treating acne, particularly in adult females, highlighting its rationale, mechanism of action, and patient selection criteria. It begins with the understanding that androgens, produced by various glands, play a significant role in acne development by stimulating sebum production and inflammatory cytokines. Spironolactone serves as an antagonist to both aldosterone and testosterone, which has made it beneficial for managing conditions associated with excess androgens, like acne and hirsutism. The presentation emphasizes the broadening use of spironolactone, particularly for female patients with treatment-resistant or refractory acne, especially those with conditions like polycystic ovary syndrome (PCOS). It also discusses patient selection, indicating that spironolactone is effective even in individuals with normal serum androgen levels due to its peripheral effects on the sebaceous glands. Spironolactone has seen a dramatic rise in prescriptions, and is increasingly viewed as a first-line alternative to antibiotics for persistent acne. The discussion notes the importance of administering hormonal workups prior to starting treatment and states that spironolactone has very few contraindications. Overall, it concludes that spironolactone's utility extends beyond just treating adult female acne and that it is a well-tolerated and effective option, deserving more recognition in dermatological practice.

View more

Conclusions

  • Spironolactone is effective for treating acne primarily due to its anti-androgenic properties.
  • The drug treats women with refractory and treatment-resistant acne, often related to conditions like PCOS.
  • It is beneficial for treating concomitant conditions such as hirsutism and alopecia alongside acne.
  • Spironolactone serves as an antibiotic alternative, addressing concerns over antibiotic resistance in acne treatment.
  • The use of spironolactone has increased significantly, particularly among adult female patients with acne from 2004 to 2013.
  • Patients with normal androgen levels can still benefit from spironolactone due to peripheral hyperandrogenism.
  • Careful patient selection is key and includes assessment of hormonal status and treatment history.
  • While there are some theoretical contraindications for spironolactone use, many concerns have been mitigated by review data.
  • The treatment requires ongoing conversation about its appropriateness and safety, especially regarding pregnancy and lactation.
  • Spironolactone may prevent relapses after isotretinoin treatment in women with a history of acne.
  • Layton A et al. Am J Clin Dermatol 2017;18:169-191
  • Harris HH et al. JAAD 1983;8:200-203
  • Plewig G et al. Berlin: Springer; 2019. pp. 45-51.
  • Picardo M et al. Dermatol Ther (Heidelb) 2017;7(suppl 1):S43-s52
  • Downing DT et al. J Am Acad Dermatol. 1986;14(2 Pt 1):221-225.
  • Searle TN et al. Clin Exp Dermatol 2020;45(8):986-993
  • Menard RH J Biol Chem 1979;254:1726-33
  • Williams M, Cunliffe J Lancet 1973;2:1055-7
  • Bernardesla E. Int J Tissue Res, 1968;10:115-9
  • Akamatsu H et al JID 1993;100:660-2
  • White GM et al. J Am Acad Dermatol. 1998;39(2):S34-S37
  • Goulden V et al. J Am Acad Dermatol. 1999;4
  • Slayden SM et al. Fertil Steril 2001;275:889-902
  • Lucky AW et al. JID 1983;81:70-74
  • de Cunla et al. Dermatology 2013;226:167-171
  • Carmina E et al. J Endocrinol Soc 2022;6:1-11
  • Ramezani F et al. Gynecol Endocrinol 2021;37:392-405
  • Guzman AK, Barbieri JS JAAD. 2016;75(6):1142-1150
  • Zaenglein AL et al. JAAD. 2016;74:945-973
  • Straight CE et al. JAAD 2015;72(5):822-827
  • Lee YH et al. JAAD 2016;71(1):70-72
  • Del Rosso JQ, Kim GK. Dermatol Ther. 2009;22:398-406
  • Del Rosso JQ et al. J Clin Aesthet Dermatol 2019;12(6):30-41
  • Morales-Cardona CS and Sanchez-Vanegas G. Actas Dermosiliogr 2013;104(1):61-66
  • Kim GK, Michaels BB. J Drugs Dermatol. 2012;11(6):708-713
  • Leyden JJ Dermatology 1997;195 Suppl 1:29-33
  • George R et al. Sem Cutan Med Surg. 2008;27(3):188-196
  • Sato et al. Aesthet Plast Surg 2006;30:689-694
  • Bommareddy K JAMA Derm 2022;158(3):275-280
  • Hiebert BM et al. Br J Clin Pharm 2021;17(4):1801-1813
  • Antoniou T et al. CMAJ 2015;187(4):e138-43
  • Arnold JD et al. J Sex Med 2016;13(11):1775-1777
  • Shields A et al. JAAD 2023;88(6):1396-1397
  • Wang C et al. Clin Cosmet Invest Dermatol. 2023;16:603-612
  • Batternick J et al. Cochrane 2010, Issue 8
  • Liu L et al. Clin Exp Hypertens 2017;39(3):257-268
  • Garg V et al. J Am
  • Biggar RJ et al. Cancer Epidemiol 2013;37(6):870-875
  • Bommareddy K et al. JAMA Dermatol 2022;158:275-82
  • Plovanich M et al. JAMA Dermatol 2015;15(9):941-54
  • Thiede RM et al. Int J Womens Derm 2019;5(3):155-159
  • Roberts EE et al. Pediatr Dermatol 2021;38(1):72-76